亚型内异质性在KMT2A中塑造了治疗反应 - - 在所有年龄组中重新安排了ALL
Alina M Hartmann1,2,3, Lorenz Bastian1,2,3, Malwine J Barz1,2,3
1Medical Department II, Hematology and Oncology University Medical Center Schleswig-Holstein, Campus Kiel Kiel Germany.
HemaSphere
|February 26, 2026
概括
在KMT2A重组的B细胞急性淋巴细胞白血病 (KMT2A r B-ALL) 中,治疗反应取决于患者的年龄和细胞成熟度. 未成熟的KMT2A r B-ALL病例显示出明显的药物敏感性,指导未来的治疗策略.
科学领域:
- 血液学 血液学 血液学
- 分子生物学分子生物学
- 遗传学 遗传学 是一个
背景情况:
- 重组KMT2A的B细胞急性淋巴细胞白血病 (KMT2A r B-ALL) 是一个具有显著异质性的高风险亚型.
- 在KMT2A r B-ALL中早期治疗反应的决定因素尚未得到充分理解,这阻碍了有效的治疗策略.
研究的目的:
- 在广泛的年龄范围内确定影响KMT2A r B-ALL诱导化疗早期治疗反应的因素.
- 整合基因组,转录组和功能药物反应数据,以了解治疗变异性.
主要方法:
- 对465例KMT2A r B-ALL病例 (1个月至89岁) 的分析.
- 将转录组和基因组分析与功能性药物反应测试的整合.
- 评估可测量的残留疾病 (MRD) 动力学和与临床和分子特征的相关性.
主要成果:
- 可测量的残留疾病 (MRD) 清除与患者的年龄,不成熟度 (低成熟度得分) 和AFF1融合伙伴相反相关.
- 细胞成熟度和KMT2A融合伙伴显著影响MRD清除.
- 一个基因表达分类器确定了细胞特征 (染色体组织,免疫调节,增殖) 与MRD清除和ex vivo药物敏感性之间的联系.
- 未成熟的KMT2A r B-ALL病例对Venetoclax的敏感性更高.
结论:
- 细胞发育状态是KMT2A r B-ALL.治疗反应的关键决定因素.
- 对发育表型,融合伴侣和MRD动态的相互作用的洞察力可以为风险适应策略提供信息.
- 有针对性的治疗方法,特别是对于不成熟的KMT2A r B-ALL,可能会改善结果.
相关概念视频
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
54
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
54
02:50Combination Therapies and Personalized Medicine
6.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K